![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
![[thumbnail of Original Article]](https://edoc.mdc-berlin.de/style/images/fileicons/application_pdf.png) |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Additional File]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Additional File)
58kB |
| Item Type: | Article |
|---|---|
| Title: | High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients |
| Creators Name: | Ilm, K., Kemmner, W., Osterland, M., Burock, S., Koch, G., Herrmann, P., Schlag, P.M. and Stein, U. |
| Abstract: | BACKGROUND: The metastasis-associated in colon cancer 1 (MACC1) gene has been identified as prognostic biomarker for colorectal cancer (CRC). Here, we aimed at the refinement of risk assessment by separate and combined survival analyses of MACC1 expression with any of the markers KRAS mutated in codon 12 (KRAS G12) or codon 13 (KRAS G13), BRAF V600 mutation and MSI status in a retrospective study of 99 CRC patients with tumors UICC staged I, II and III. FINDINGS: We showed that only high MACC1 expression (HR: 6.09, 95% CI: 2.50-14.85, P < 0.001) and KRAS G13 mutation (HR: 5.19, 95% CI: 1.06-25.45, P = 0.042) were independent prognostic markers for shorter metastasis-free survival (MFS). Accordingly, Cox regression analysis revealed that patients with high MACC1 expression and KRAS G13 mutation exhibited the worst prognosis (HR: 14.48, 95% CI: 3.37-62.18, P < 0.001). Patients were classified based on their molecular characteristics into four clusters with significant differences in MFS (P = 0.003) by using the SPSS 2-step cluster function and Kaplan-Meier survival analysis. CONCLUSION: According to our results, patients with high MACC1 expression and mutated KRAS G13 exhibited the highest risk for metachronous metastases formation. Moreover, we demonstrated that the "Traditional pathway" with an intermediate risk for metastasis formation can be further subdivided by assessing MACC1 expression into a low and high risk group with regard to MFS prognosis. This is the first report showing that identification of CRC patients at high risk for metastasis is possible by assessing MACC1 expression in combination with KRAS G13 mutation. |
| Keywords: | KRAS Mutations, MACC1, Prognostic Marker, Colorectal Cancer, Metastasis-Free Survival |
| Source: | Molecular Cancer |
| ISSN: | 1476-4598 |
| Publisher: | BioMed Central |
| Volume: | 14 |
| Number: | 1 |
| Page Range: | 38 |
| Date: | 14 February 2015 |
| Official Publication: | https://doi.org/10.1186/s12943-015-0316-2 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
